Social Network Clustering Analysis for Detection of Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLC
Life · 26.06.2026 · 16 (7) · 1071
DOI: 10.3390/life16071071 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life, online erschienen am 26.06.2026. Verfasst von Abed Agbarya und 11 weiteren Autor:innen. Beteiligte Einrichtung: The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel. Die Arbeit nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer (NSCLC) exhibits genomic heterogeneity that affects tumor immunogenicity and PD-L1 expression. Patient clustering based on shared mutational profiles using social network analysis (SNA) has been narrowly explored. The study aimed to identify subgroups of NSCLC patients with similar somatic mutation profiles using network-based modularity clustering, and to compare these groups with respect to PD-L1 expression, Tumor mutation burden (TMB), and clinical variables. Data of patients with stage 4 (metastatic) NSCLC, whose tumor tissue samples were collected between 2022 and 2024, were analyzed. This retrospective study included NSCLC patients harboring actionable driver mutations in genes such as EGFR, KRAS, ALK, BRAF, MET. A social network of 129 patients was constructed. Two distinct genomic clusters were identified. Cluster 2 (n = 55) showed a higher prevalence of KRAS, TP53, BRAF, STK11 and additional mutations, while cluster 1 (n = 74) displayed a limited number of driver mutations. Cluster 2 had significantly higher PD-L1 expression (29.8% vs. 13.7%, p = 0.001) and higher TMB (7.8 vs. 5.8, p = 0.021). In multivariate logistic regression, both PD-L1 and TMB were associated with cluster assignment (p < 0.05). Mutation-based SNA clustering delineated two biologically distinct subgroups of NSCLC patients. The highly mutated cluster displayed higher PD-L1 expression and TMB, a profile consistent with a more immunogenic phenotype. This method offers a novel integrative approach that requires prospective validation before clinical implementation.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa 3109601, Israel.
- Department of Oncology, Bnai-Zion Medical Center, Haifa 3339419, Israel.
- The Joseph Fishman Oncology Center, Rambam Medical Center, Haifa 3525409, Israel.
- Pathology Institute, Lady Davis Carmel Medical Center, Haifa 3436212, Israel.
- The Legacy Heritage Cancer Center, Dr. Larry Norton Institute, Soroka Medical Center, Beer Sheva 8457108, Israel.
- Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva 8410501, Israel.
ORCID-Profile: Abed Agbarya, Walid Shalata, Leonard Saiegh, Dan Levy-Faber
Zitieren
APA
Agbarya, A., Nasrallah, H., Mhameed, K., Sabo, E., Shalata, W., Liani, E., Mazareb, S., Sheikh-Ahmad, M., Saiegh, L., Radonjic, D., Sebek, V., & Levy-Faber, D. (2026). Social Network Clustering Analysis for Detection of Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLC. Life, 16(7), 1071. https://doi.org/10.3390/life16071071
Vancouver
Agbarya A, Nasrallah H, Mhameed K, Sabo E, Shalata W, Liani E, et al. Social Network Clustering Analysis for Detection of Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLC. Life. 2026;16(7):1071. doi:10.3390/life16071071
BibTeX
@article{Agbarya2026,
author = {Agbarya, Abed and Nasrallah, Haitham and Mhameed, Kamel and Sabo, Edmond and Shalata, Walid and Liani, Esti and Mazareb, Salam and Sheikh-Ahmad, Mohammad and Saiegh, Leonard and Radonjic, Dejan and Sebek, Viktor and Levy-Faber, Dan},
title = {Social Network Clustering Analysis for Detection of Associated Genetic Co-Mutations in Patients with Actionable Driver Mutations in NSCLC},
journal = {Life},
year = {2026},
volume = {16},
number = {7},
pages = {1071},
doi = {10.3390/life16071071}
}
EUVIMED